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ABSTRACT
Multiply myeloma (MM) grows in and destroys bone, where osteocytes secrete 
FGF23, a hormone which affects phosphate homeostasis and aging. We report that 
multiple myeloma (MM) cells express receptors for and respond to FGF23. FGF23 
increased mRNA for EGR1 and its target heparanase, a pro-osteolytic factor in MM. 
FGF23 signals through a complex of klotho and a classical FGF receptor (FGFR); both 
were expressed by MM cell lines and patient samples. Bone marrow plasma cells from 
42 MM patients stained positively for klotho, while plasma cells from 8 patients with 
monoclonal gammopathy of undetermined significance (MGUS) and 6 controls were 
negative. Intact, active FGF23 was increased 2.9X in sera of MM patients compared 
to controls. FGF23 was not expressed by human MM cells, but co-culture with mouse 
bone increased its mRNA. The FGFR inhibitor NVP-BGJ398 blocked the heparanase 
response to FGF23. NVP-BGJ398 did not inhibit 8226 growth in vitro but significantly 
suppressed growth in bone and induction of the osteoclast regulator RANK ligand, 
while decreasing heparanase mRNA. The bone microenvironment provides resistance 
to some anti-tumor drugs but increased the activity of NVP-BGJ398 against 8226 
cells. The FGF23/klotho/heparanase signaling axis may offer targets for treatment 
of MM in bone. 
INTRODUCTION
Multiple myeloma (MM) is a hematological 
malignancy in which osteolytic bone disease due to tumor 
stimulation of osteoclasts and suppression of osteoblasts 
causes severe morbidity and is associated with poor 
prognosis [1]. Palliative treatments for MM bone disease 
rely on inhibitors of osteolysis such as bisphosphonates 
or RANK ligand-neutralizing antibody. Crosstalk between 
MM cells and bone remains incompletely understood, 
and direct molecular interactions between myeloma and 
factors unique to the bone microenvironment have not 
been described. 
Osteocytes are the most abundant cell type within 
bone and source of the endocrine hormone FGF23. Unlike 
most fibroblast growth factors (FGFs), FGF23 lacks high 
affinity for heparin sulfate, which recruits ligands to FGF 
receptors (FGFRs). Assembly of FGFRs 1, 3 or 4 with 
transmembrane klotho forms specific receptors for FGF23 
[2]. FGF23 acts on FGFR/klotho-expressing kidney tubule 
cells, where it regulates phosphate homeostasis and 
maintains the concentration of 1,25-dihydroxyvitamin D 
in its normal physiological range. Loss of FGF23 signaling 
may account for much of the aging phenotype of klotho-
deficient mice, consequent to hyperphosphatemia and 
hypervitaminosis D, which can be ameliorated by dietary 
or genetic manipulations [3]. 
Klotho was discovered when an accidental gene 
inactivation in mice caused premature aging [4]. Klotho 
is an evolutionarily conserved protein with membrane-
anchored and secreted forms and two major duplicated 
glycosyl hydrolase domains. In addition to serving as an 
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FGF specificity co-receptor, klotho can inhibit insulin/
IGF-1, Wnt and TGFβ signaling, suppress oxidative stress, 
and alter the activity of the TRPV5 calcium channel [5-
8]. Over 80 publications have studied klotho in a variety 
of cancer types, with actions including effects on aging, 
inhibition of IGF-1, FGF2 and TGFβ signaling and tumor 
suppressor function [9, 10]. Tumor cells were not tested in 
these papers for the major physiological function of klotho 
to mediate cellular responses to FGF23. 
FGFR signaling regulates the growth and 
progression of many cancers including MM [9], but a role 
for FGF23 in MM has not been reported. Since FGF23 is 
secreted by osteocytes, high concentrations of the factor 
will occur in the bone microenvironment - leading us to 
test a role for FGF23 in MM bone disease by asking if 
MM cells express receptors for and respond to FGF23. 
RESULTS 
FGF23 increases EGR1 and heparanase 
Bone-metastatic breast and other cancer cell lines 
often express klotho [9], but tumor responses to FGF23 
have not been reported. We asked whether MM cell lines 
responded to FGF23. FGF23 did not affect growth of MM 
cells in vitro (Supplementary Figure S1). In kidney tubules, 
FGF23 increases the early gene response transcription 
factor EGR1 [11]. When MM cell lines were treated with 
100ng/ml FGF23, EGR1 mRNA was increased 2-10X at 
1 hour and declined by 4 hours in RPMI-8226 and JJN3 
(Figure 1A and 1C) and three additional MM cell lines 
(Supplementary Figure S2). A literature search for EGR1-
responsive genes with roles in cancer and bone identified 
heparanase [12], an enzyme that significantly contributes 
to myeloma bone disease [13]. Heparanase mRNA was 
Figure 1: FGF23 regulates MM gene expression. (A) and (C) FGF23 induces EGR1 in MM cells. Time courses (0-24hrs) of 
induction of EGR1 mRNA determined by PCR in RPMI-8226 (A) and JJN3 (C) myeloma cells in response to 100ng/ml FGF23. For 
both cell lines the increase in EGR1 mRNA at one hour was significant versus zero hours at p < 0.001. (B) and (D) Effects of FGF23 on 
heparanase (HPSE) expression. Time courses as in panels (A) and (C). Results for RPMI-8226 (B) and JJN3 (D) cells. Increases at 1 and 
24 hours in heparanase mRNA were significant in both cell lines at p < 0.001.
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increased in RPMI-8226 and JJN3 cells 18-fold and 4-fold 
respectively by FGF23 (Figure 1B and 1D). We focused 
on these two human MM cell lines, since they cause 
osteolytic bone destruction in mouse models [14, 15]. 
Heparanase mRNA was unchanged in three other MM cell 
lines (Supplementary Figure S2). The t5 alternate form of 
heparanase found in renal cancers [16] was not increased 
by FGF23 (Supplementary Figure S3). 
MM cells express klotho
FGF23 signals by high affinity binding to complexes 
between a classical FGFR and klotho [2]. FGFRs are 
abundantly expressed in MM [17], but klotho has not 
been reported in myeloma cells, which we next tested. 
Bone marrow clots and aspirate smears from 42 patients 
with MM, 8 subjects with MGUS and 6 normal controls 
were stained with klotho antibody. Normal kidney was the 
positive control, with distal convoluted tubules staining 
intensely (Figure 2A). Klotho immunostaining was seen 
in plasma cells in all myeloma cases (Figure 2B and 2C). 
Klotho was localized to the cytoplasm of MM (Figure 
2D) as punctate granules. In MGUS, there was minimal 
to no cytoplasmic staining in occasional plasma cells 
(Figure 2E) and no staining of plasma cells in normal bone 
marrow (Figure 2F). Compared to non-MM plasma cells, 
klotho expression by MM cells was significantly increased 
(p < 0.01, Figure 2G) when staining was scored blind on 
a standard scale. No relationship was observed between 
percent MM cells in bone marrow and intensity of klotho 
staining. No significant association was observed between 
the klotho staining and disease features, including staging 
and extent of bone involvement. 
Serum klotho is unchanged in MM 
We asked if serum soluble klotho was altered in 
MM, using an ELISA that recognizes secreted and shed 
forms [18]. Detection of both forms was confirmed 
with supernatants from cultures of breast cancer cells 
transfected with membrane-bound, secreted (549 amino 
acid) or the 980 amino acid extracellular domain of klotho 
(Supplementary Information). High concentrations of 
klotho were found in similar amounts in media from cells 
expressing each of the forms of klotho (data not shown). 
Soluble klotho concentrations did not differ (p = 0.39) 
between MM patients (n = 33, mean ± SD = 670 ± 458 pg/
ml) and controls (n = 43, 598 ± 269 pg/ml) (Figure 2H). 
Concentrations of soluble klotho were below the limit of 
detection (<6.15 pg/ml) in media conditioned by four MM 
cell lines (data not shown). We found klotho mRNA in 
four human MM cell lines (Figure 2I) and purified CD138+ 
primary cells from four patients (Figure 2J). The cell lines 
expressed both membrane and secreted klotho mRNAs 
(Supplementary Figure S4). Patient samples and cell lines 
also expressed mRNAs encoding at least two of the three 
FGFRs that couple to klotho (Supplementary Figure S5). 
Serum intact FGF23 is increased in MM
 Mean Intact FGF23 concentrations were 2.9 fold 
higher in 33 newly diagnosed MM patients compared to 
186 controls (106 ± 157 pg/ml and 36 ± 17 pg/ml; p < 
0.0001) (Figure 3A). MM is a relatively rare malignancy: 
our patient population was sufficient to provide statistical 
significance, but not large enough to show differences 
between subgroups when the MM samples were stratified 
according to degree of bone involvement (Supplementary 
Figure S6). To test if myeloma cells were a source of 
circulating FGF23, cell lines and primary MM cells were 
analyzed by real-time PCR. FGF23 messenger RNA was 
undetectable (four myeloma cell lines, Figure 3B) or much 
lower (four primary patient samples, Figure 3C) than the 
positive bone control. 
Co-culture with MM increases FGF23 expression 
in bone
 The co-culture assay modifies a standard procedure 
for growing mouse bone ex vivo [19], by the addition of 
human tumor cells [20]. We adapted it for MM cell lines 
and analyzed changes in tumor and bone markers after 
one week by species-specific real-time PCR to distinguish 
between mouse bone and human MM mRNAs. RPMI-
8226 or JJN3 human MM cells significantly increased 
mouse FGF23 mRNA 2-fold and 5-fold respectively, 
compared to bones without added MM cells (Figure 4). 
FGFR inhibition affects tumor growth
Next we tested if an inhibitor of FGF23 signaling 
altered myeloma growth in bone. The dose-response to 
FGF23 was first determined in vitro. FGF23 at 3ng/ml 
(1.2x10-10M) significantly induced heparanase mRNA 
(Figure 5A). The pan-selective FGFR inhibitor NVP-
BGJ398 dose-dependently blocked the response to 10ng/
ml FGF23 (Figure 5B), from which we chose 25 or 40nM 
(14 or 22ng/ml) to test against growth of MM cells stably 
secreting Gaussia luciferase [21] to follow tumor burden 
[22]. The drug dose-dependently inhibited growth of JJN3 
cells in vitro at 7 days (Figure 5C), while 25nM decreased 
MM activity in bone over the same time (Figure 5D). 
In contrast, RPMI-8226 cells were resistant to 40nM 
inhibitor in vitro (Figure 5E), but the same concentration 
significantly decreased their activity in bone (Figure 5F).
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Figure 2: Klotho expression by multiple myeloma. (A)-(F) Representative color images of klotho IHC. Kidney positive control 
(A), representative cases of multiple myeloma (B) and (C), bone marrow smear from a myeloma case (D), MGUS (E), and normal plasma 
cell (F), with arrows pointing at plasma cells. (G)-(J) Klotho staining and mRNA expression by MM. (G) Intensity of klotho IHC staining 
of plasma cells from normal (●), MGUS (▪) and myeloma ( Δ) bone marrow samples (from Table 1) (p < 0.01 for MM versus normal or 
MGUS groups). Staining intensities were compared using ANOVA on ranks. (H) Serum concentrations of soluble klotho did not differ 
between 33 patients with MM and 43 controls (p=not significant). Y axis shows soluble klotho concentrations (pg/ml). Black horizontal 
lines represent mean klotho levels in each group. Vertical brackets represent ± one standard deviation. The distribution of variables was 
examined, and appropriate normalizing transformations were performed where needed for soluble klotho and serum intact FGF23 in the 
next Figure. Serum FGF23 and klotho concentrations in MM and controls were compared using unpaired t-tests for means. In addition, 
correlations between klotho or FGF23 levels and creatinine levels, Cockroft-Gault estimated glomerular filtration rate (GFR), as well as 
serum phosphate levels, were evaluated using Spearman correlation. (I) and (J) Klotho mRNA in MM. Real-time PCR for total klotho 
in four human MM cell lines (NCI-H929, U266, RPMI-8226, MM.1S) and breast cancer cell lines MDA-MB-231 and MCF7 [10]. Data 
are reported as fold differences in mRNA levels compared to that of breast cancer cells MCF-7, which express moderate klotho and are 
arbitrarily set at 1 (I). Klotho mRNA in 4 primary patient samples (PT1088, PT1099, PT1100 and PT1104) compared to that of 8226 MM 
cells set at 1 (J). 
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Figure 3: Serum intact FGF23 was higher in MM patients compared to controls, while MM cells made little FGF23 
mRNA. (A) Serum intact FGF23 concentrations (pg/ml) from 186 controls and 33 MM patients, determined by ELISA. Mean concentrations 
were 2.9 fold higher in patients with MM (p < 0.0001) compared to controls. Vertical brackets indicate ± 1 standard deviation from the mean 
(black horizontal lines). FGF23 mRNA levels in MM cell lines (B) and four primary patient samples (C) by real-time PCR. Human bone 
total RNA was the positive control for FGF23. 
Figure 4: MM cells induce bone expression of FGF23. Myeloma cells (104) were co-cultured with calvarial bone sections from 
B6.SJL-PtprcaPep3b/BoyJ mouse pups for 7 days and expression of bone FGF23 analyzed by Q-PCR with species-specific primers for 
mouse FGF23. Contact with RPMI-8226 (A) or JJN3 (B) human MM cells significantly increased bone FGF23 mRNA (p < 0.001).
Oncotarget19652www.impactjournals.com/oncotarget
FGFR inhibition alters MM and bone gene 
expression
Finally, we asked if FGF signaling inhibition altered 
bone responses to tumor. The co-cultures from Figure 5D 
and 5F were processed for RNA isolation and analyzed 
by Q-PCR with mouse-specific primers for bone markers: 
RANKL, the central regulator of osteoclastogenesis 
(Figure 6A) and tartrate-resistant acid phosphatase 
(TRAP) a major osteoclast enzyme (Figure 6B) were 
increased by myeloma cells. The increase in RANKL 
was opposed by NVP-BGJ398 treatment. TRAP was less 
affected, but osteoclast activity may have peaked before 
day 7 when the cultures were assayed. Type 1 collagen, 
a major product of metabolically active osteoblasts was 
increased by drug treatment in the presence of MM cells 
(Figure 6C), while NVP-BGJ398 had a modest effect to 
oppose the increase of FGF23 in the presence of MM 
cells (Figure 6D). Finally, we found that the pan-FGFR 
inhibitor decreased the FGF23 target heparanase in the 
two MM cell lines grown in bone, when analyzed by 
Q-PCR with human-specific primers (Figure 6E).
DISCUSSION 
Greater than 80% of patients with multiple myeloma 
develop osteolytic bone disease, due to osteoclast 
activation and osteoblast suppression, leading to skeletal-
related events, including severe bone pain, vertebral 
compression and pathologic fractures [1]. No specific 
molecular actions on MM by factors unique to bone have 
been reported previously, prompting us to ask if such 
factors might contribute to myeloma growth in bone. We 
Table 1: Patient characteristics. 
Bone marrow samples
Characteristics Newly diagnosed Myeloma (n=42) MGUS (n= 8) Normal (n= 6)
Age (years) 41-76 (median = 63) 56-68 (median 59)
45-67 (median 
56)
Sex (Male/Female) 25/17 5/3 3/3
Stage (percent)
I
II
III
16 (38%)
16 (38%)
10 (24%)
N/A N/A
Bone involvement (percent)
No lytic lesions
<5 lesions
≥ 5 lesions
8 (19%)
7 (17%)
27 (64%)
Serum Samples Newly diagnosed MM (n=33)
Age 41-78 (median 62)
Sex (Male/Female) 20/13
Stage (percent)
I
II
III
16 (48%)
11 (33%)
6 (18%)
Bone involvement (percent)
No lytic lesions
<5 lesions
≥ 5 lesions
7 (21%)
6 (18%)
20 (60%)
Serum creatinine (mg/dl) 0.55-2.50 (Mean=1.20 ± 0.5)
Cockroft-Gault estimated glomerular 
filtration rate (ml/minute) 25 to 102 (Median = 53)
Serum phosphate (mg/dl) (n=25) 1.80-5.83 (mean  4.2 ± 1.0)
No statistically significant association was observed between the klotho staining and disease features, including staging 
and extent of bone involvement. In our sample set where most patients have normal or mild renal insufficiency (based on 
serum creatinine and Cockroft-Gault Estimated GFR), we did not observed a correlation between serum intact FGF23 and 
serum klotho, serum creatinine, Cockcroft-Gault calculated GFR, or serum phosphate levels (p>0.05).  In 15 cases where 
both serum and bone marrow samples were available, there was no correlation between serum klotho concentrations and 
klotho expression by immunostaining.
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Figure 5: Pan-FGFR kinase inhibitor blocks responses to FGF23 in vitro and growth of MM in bone. (A) Dose-response 
to FGF23 of RPMI-8226 cells for induction of heparanase mRNA at 24hrs. Cells treated with recombinant human FGF23 between 1 and 
100ng/ml and analyzed as in Figure 1C. (B) Increased heparanase mRNA in RPMI-8226 cells in response to 10ng/ml FGF23 was dose-
dependently blocked by the pan-FGFR kinase inhibitor NVP-BGJ398. (C)-(E) MM tumor burden assayed as secreted Gaussia luciferase 
from stably transduced cells. (C) Dose-dependent inhibition of JJN3 cells in vitro by NVP-BGJ398. (D) Inhibition by 25nM NVP-BGJ398 
of 5,000 JJN3 cells added to Swiss Webster neonatal mouse calvariae. (E) Lack of inhibition of RPMI-8226 cells in tissue culture by 40nM 
NVP-BGJ398. (F) Inhibition at 4 and 7 days with 40nM NVP-BGJ398 of 5,000 8226 MM cells in bone, as in (D), with calvariae from 
B6.SJL-PtprcaPep3b/BoyJ mice: significant versus control at p < 0.01. 
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Figure 6: Effects of pan-FGFR kinase inhibitor on bone cell and MM responses in co-culture. Species-specific PCR 
analyses of calvariae incubated for 7d with 5,000 RPMI-8226 or JJN3 MM cells and treated ± NVP-BGJ398. (A)-(D) Expression of 
bone genes analyzed with mouse-specific primers. (A) Regulator of osteoclastogenesis, RANK ligand. (B) Osteoclast marker, TRAP. (C) 
Osteoblast biosynthetic activity marker, type 1 collagen. (D) Osteocyte marker, FGF23. (A)-(C) Combine data from separate experiments 
with B6.SJL-PtprcaPep3b/BoyJ mouse calvariae (left-hand four bars with [NVP-BGJ398] = 40nM) and Swiss Webster calvariae (right-
hand six bars, with [NVP-BGJ398] = 25nM). (E) Myeloma cell expression of human heparanase in presence of Swiss Webster calvariae ± 
25nM NVP-BGJ398. Comparisons for significance are between untreated and treated pairs. (E) includes convention for bar labeling used 
in all panels.
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focused on osteocytes as the most abundant cell type in 
the skeleton and main source of bone-derived endocrine 
factors, including FGF23 [23]. 
To test if FGF23 activates signaling in myeloma 
cells, we assessed EGR1, an early response transcription 
factor induced by FGF23 in kidney tubules [11]. EGR1 
mRNA was rapidly increased in five MM cell lines 
(Figure 1A and 1C and Supplementary Figure S2A, S2C 
and S2E), while growth or apoptosis in vitro of three 
human MM cell lines was unaffected by FGF23 treatment 
(Supplementary Figure S1 and data not shown). EGR1 
transcriptionally regulates a plethora of genes in many 
cell types [24]. In prostate cancer it is tumorigenic and 
pro-metastatic, activating secretion of growth factors and 
enzymes that modify extracellular matrix. A significant 
transcriptional target of EGR1 is heparanase [12, 25], 
a central regulator of osteolysis and growth in bone of 
myeloma and solid tumors [13] (additional references in 
Supplementary Information). FGF23 strongly increased 
heparanase in RPMI-8226 and JJN3 MM cell lines (Figure 
1B and 1D). The short, alternative t5 form of heparanase 
expressed by renal cancers [16] was not increased by 
FGF23 (Supplementary Figure S3). The results show 
that FGF23 has direct actions on MM cells. In prostate 
or breast adenocarcinoma and colon carcinoma cell lines 
de Mestre et al [12] observed that heparanase mRNA was 
increased at 24hrs, by which time EGR1 mRNA (stimulate 
by PMA treatment of the cells) had returned to baseline 
- as expected for an early response gene. In Figure 1 we 
observed the same temporal relationship between EGR1 
and heparanase in FGF23-treated MM cell lines. The MM 
cell lines that did not show increased heparanase mRNA 
upon treatment (Supplementary Figure S2) expressed 
much higher basal message than the JJN3 and RPMI-8226 
cell lines that showed strong induction of heparanase by 
FGF23. 
Heparanase is a centrally important regulator of 
metastases, tumor microenvironment interactions, and 
bone metabolism via actions on many targets [25, 26]. 
High heparanase is an indicator of poor prognosis in MM 
[27]. It increases local expression of proteases [28] and 
RANK ligand [13], the central regulator of osteoclasts. 
It also suppresses osteoblast activity [29] - a hallmark of 
myeloma bone disease [1]. 
We asked if myeloma cells express FGF23 
receptors [11]. FGF23 lacks high affinity for heparan 
sulfate proteoglycans, which increase FGFR affinity for 
conventional FGF ligands. Instead, a C-terminal extension 
of FGF23 confers high affinity for the klotho:FGFR 
complex [2]. Klotho is expressed in many tumor types, 
increasing with progression in ovarian cancer [30] while 
decreasing in breast cancer [10]. MM express FGFRs 
[17, 31], but klotho expression has not been reported. 
We found klotho IHC staining in all MM samples tested, 
while a small sample of normal plasma cells and MGUS 
bone marrow aspirates was negative (Figure 2B-2G) with 
a well-characterized monoclonal antibody [32] previously 
used in kidney (Figure 2A) and in small cell lung cancer 
samples [33]. While klotho is a transmembrane protein, its 
immunostaining was frequently intracellular (Figure 2D). 
The klotho:FGFR complex could be endocytosed upon 
ligand binding, causing the punctate cytoplasmic staining 
observed. Figure 2G suggests that klotho expression (and 
potential FGF23-responsiveness) may be a hallmark 
of the transformation of plasma cells into MM. Normal 
plasma cells from additional patients need to be analyzed 
to confirm this. FGF23 signaling ensues when ligand 
binds to klotho plus FGFRs 1, 3 or 4 [34]. Four standard 
human MM cell lines and four primary patient samples 
all expressed klotho mRNA (Figure 2I and 2J). CD138+ 
primary MM cells expressed FGFRs 3 and 4 but not 
significant amounts of FGFR1, while the cell lines RPMI-
8226 and JJN3 expressed FGFRs 1 and 4 (Supplementary 
Figure S5), predicting that all should be responsive to 
FGF23.
Stewart et al previously reported that serum FGF23 
levels were increased in patients with myeloma and 
correlated with serum paraprotein [35]. The authors’ 
ELISA used polyclonal antibodies against C-terminal 
epitopes, consequently detecting both biologically active 
intact FGF23 and inactive C-terminal fragments [36]. 
Only intact FGF23 activates the membrane klotho:FGFR 
complex. C-terminal fragments may compete with intact 
FGF23 for receptor binding and have antagonist functions 
[37]. Imel et al demonstrated that in healthy subjects, 
C-terminal FGF23 concentrations are frequently elevated 
when intact FGF23 and phosphorus concentrations remain 
normal [38]. Thus C-terminal FGF23 and intact assays 
provide different information. We found increased intact 
FGF23 (Figure 3A) in MM serum but cannot exclude 
the presence of inactive FGF23 fragments. Stewart et al 
[35] proposed that MM cells make FGF23 on the basis 
of immunostaining, which could be due to binding of 
exogenous FGF23 to receptors or nonspecific binding. 
Ectopic FGF23 expression has only been reported in rare 
mesenchymal tumors associated with hypophosphatemic 
tumor-induced osteomalacia, due to renal phosphate 
loss [39] - a feature not seen in myeloma. We failed to 
detect significant amounts of FGF23 mRNA in MM cell 
lines or primary MM samples (Figure 3B and 3C). Our 
CD138-positive primary cells were rapidly purified by 
cell sorting from marrow aspirates to decrease bone cell 
contamination as a source of FGF23. It is not possible to 
distinguish myeloma cells being devoid of FGF23 mRNA 
but contaminated with bone cells, versus low expression 
of FGF23 by MM cells. A larger controlled study is 
required to resolve this issue. We conclude that MM cells 
are not a significant source of FGF23. We did not observe 
differences in FGF23 levels between groups with different 
degrees of bone involvement (Supplementary Figure 
S6). The relationship of serum FGF23 to extent of bone 
involvement needs to be tested in a larger cohort of MM 
Oncotarget19656www.impactjournals.com/oncotarget
patients using accurate assessment of bone involvement. 
The presence of myeloma cells could stimulate 
osteocyte secretion of FGF23, leading to its elevation 
in patient sera. We tested if MM cells increased bone 
production of FGF23, using a novel ex vivo assay where 
tumor cells are added to primary bone organ cultures [19]. 
Neonatal mouse calvariae are immune-naïve and support 
growth of human solid tumor cell lines [20] that cause bone 
metastases in mouse models. We added small numbers of 
MM cells and monitoring gene changes in tumor cells 
(human) and bone cells (mouse) by real-time PCR with 
species-specific primers [40] to distinguish the cellular 
source of mRNAs in the mixed species co-cultures. Bone 
expression of FGF23 mRNA was significantly increased 
2-5 fold after one week of co-culture with myeloma 
cells (Figure 4). Thus, increased circulating FGF23 in 
patients may result from MM stimulation of osteocytes. 
Studies are under way to identify myeloma-derived 
factors that increase FGF23 production. Other factors that 
might affect circulating FGF23 concentrations include 
bisphosphonates, renal function and iron status. However, 
patient bisphosphonate use decreases FGF23 [41]. Despite 
high intact FGF23 levels, serum phosphate concentrations 
were largely normal in our sample set, suggesting that 
other factors maintain phosphate homeostasis. Iron 
deficiency correlates with elevated C-terminal FGF23 
[42]. Imel et al reported, in a study of autosomal dominant 
hypophosphatemic rickets (ADHR), that low serum 
iron was associated with elevated C-terminal but not 
intact FGF23 in control subjects, while increased intact 
molecule was also negatively correlated with iron in 
ADHR patients. The results suggest that FGF23 cleavage 
is a compensatory mechanism to maintain active FGF23 
in the normal range [38]. MM-related anemia is due to 
impaired iron utilization, rather than low iron per se [43], 
with most MM patients having normal or high iron status, 
making it unlikely to explain high FGF23. Parathyroid 
hormone receptor activation increases bone expression of 
FGF23 [44], and MM cells may secrete its ligand, PTHrP 
[45]. Factors that can influence FGF23 levels should be 
explored in a larger cohort of MM patients, including 
1,25-dihydroxyvitamin D, PTHrP, other FGFs, low pH and 
high serum phosphate/calcium ratio [46]. 
To test a role for FGF23 in myeloma bone disease, 
we used the pan-FGFR tyrosine kinase inhibitor NVP-
BGJ398, which rapidly normalized phosphate and 
enhanced bone growth - with increased mineralization 
and normalization of growth plate structure - in a 
mouse model of ADHR, where elevated FGF23 causes 
hypophosphatemia [47]. NVP-BGJ398 effectively blocked 
the heparanase response of MM cells in vitro to 10ng/ml 
FGF23 (Figure 5B). JJN3 MM cells were highly sensitive 
to growth inhibition in vitro by NVP-BGJ398 and were 
also growth inhibited in bone co-culture, while 40nM 
NVP-BGJ398 had no effect on the growth of RPMI-8226 
cells in standard tissue culture but blocked their growth in 
bone, as monitored by secreted luciferase marker (Figure 
5E versus 5F). The bone microenvironment frequently 
confers resistance to treatment; therefore the increased 
sensitivity of 8226 to NVP-BGJ398 in bone compared 
to in vitro is of particular interest. It suggests that FGF 
targeting may alter the bone microenvironment, making it 
hostile to tumor growth - although NVP-BGJ398 showed 
few effects on bone alone. In MM:bone cocultures, it 
decreased tumor RANKL, increased osteoblastic activity 
(type 1 collagen) and decreased osteocyte FGF23 - which 
in turn should decrease tumor heparanase. Additional work 
is needed to determine if NVP-BGJ398 acts primarily 
through direct blockade of FGF23 signaling or indirectly 
through other actions on tumor, bone, or both. 
NVP-BGJ398 and several other pan-FGFR kinase 
inhibitors are in clinical development for cancer treatment 
[31, 48]. Inhibition of FGFR signaling in MM has focused 
on cells carrying activating FGFR3 mutations that cause 
‘addiction’ to FGFR signaling and confer sensitivity 
to FGFR inhibitors. A recent clinical trial of Dovitinib, 
a multikinase inhibitor with activity against FLT3/c-
Kit, FGFR1/3 and VEGFR1-4 kinases, in patients with 
relapsed or refractory MM showed marginal efficacy 
in subjects with or without FGFR3 mutations [49]. The 
reason for the treatment failure is unclear, and correlative 
data on FGFR inhibition were not reported. Participating 
patients were heavily pretreated and some died quickly 
due to disease progression; so the results do not exclude 
FGFRs as viable targets for MM treatment. We chose 
NVP-BGJ398 on the basis of its ability to block FGF23 in 
an animal model, where it caused anabolic bone responses 
[47] - which could contribute to the antitumor effects 
seen in bone. NVP-BGJ398 and other tyrosine kinase 
inhibitors selective for FGFRs, including LY2874455, 
SSR128129E, AZD4547 and PD173074, are in early 
clinical development for solid tumors. FGF signaling is 
complex and variable in different tumors at different stage. 
Better understanding of FGF signaling in MM and bone 
should clarify the potential of FGFR inhibitors for MM 
treatment.
 Our results suggest that FGF23 from skeletal 
osteocytes drives a vicious cycle [50] of myeloma 
growth in bone by binding to MM cells and activating 
transcription of pro-metastatic and pro-osteolytic genes, 
such as heparanase. Future research is needed to identify 
additional genes regulated by FGF23 and to clarify 
the mechanisms by which MM systemically increases 
active FGF23 in patients. The action of FGF23 on MM 
cells identifies targets for intervention against myeloma 
bone disease, including heparanase antagonists [51, 52], 
FGF23-neutralizing antibodies [53] and FGFR kinase 
inhibitors [48], now entering clinical trials.
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MATERIALS AND METHODS
Cell lines and materials 
Human MM cell lines RPMI-8226, U266, NCI-H929 
and MM.1s and human breast cancer cell lines MCF-7 
and MDA-MB-231 were from the ATCC and grown in 
recommended media. JJN3 human MM cells were from 
Professor N. Giuliani, University of Parma. Recombinant 
human FGF23 was from R&D Systems Inc. Anti-klotho 
antibody KM2076 is a rat IgG(2)a monoclonal antibody 
raised against residues 55-261 of human klotho protein 
[32] and was generously provided by Kyowa Hakko Kirin 
Co. Ltd., Tokyo; it is now available commercially. NVP-
BGJ398 was from ChemieTek, Indianapolis, IN.
Human specimens
All patient materials were used with informed 
consent and HIPAA compliance with a protocol approved 
by the Indiana University Institutional Review Board. 
Previously frozen serum samples obtained at diagnosis 
were available from 33 MM patients (Table 1). Serum 
FGF23 and soluble klotho data for healthy controls were 
previously analyzed by one of the authors (EAI) and used 
for comparison with myeloma samples. Serum klotho 
results were available from 43 and FGF23 from 186 
control subjects [38]. Klotho in bone marrow plasma cells 
was evaluated in paraffin-embedded bone marrow clots, 
bone marrow aspirate smears and tonsil tissues from the 
histology archives of the Department of Pathology. Bone 
marrow specimens from 42 newly diagnosed MM patients, 
8 MGUS patients, 6 healthy controls, and two normal 
tonsils were stained for klotho immunohistochemistry 
(IHC). Of these 42 patients, 15 had corresponding serum 
samples at the time of diagnosis available for klotho 
and FGF23 analyses. Patient clinical parameters are 
summarized in Table 1. 
Serum assays
Intact FGF23 was assayed as described [54] using 
ELISA kits from Kainos Laboratories (Tokyo, Japan) with 
a lower limit of detection of 3pg/ml and coefficient of 
variation of 6%. The assay recognizes only intact FGF23 
via monoclonal antibodies for epitopes on opposite sides 
of the FGF23 R176XXR179 cleavage site. Soluble klotho in 
sera and conditioned media was assayed using an ELISA 
(IBL-America), with a lower limit of detection of 6.15pg/
ml and coefficient of variation of 5% [18]. Creatinine, 
calcium and alkaline phosphatase were measured in the 
clinical pathology laboratory using standard methods. 
Glomerular filtration rates were calculated using the 
Cockroft-Gault equation. Serum phosphate was measured 
with a Roche COBAS Mira S (Roche Diagnostics), 
using reagents from Thermo Scientific. Serum phosphate 
values >6ng/dl were presumed to be secondary to either 
hemolysis or interference with the analytical reading by 
excess monoclonal protein and were excluded. 25 MM 
subjects had assessable serum phosphates. 
Immunohistochemistry
Procedures used solutions, instruments and protocols 
from Dako. Sections were cut and placed on positively-
charged slides. After removal of paraffin and washing 
with distilled water, the slides underwent antigen retrieval 
using Target Retrieval high pH solution for 20 min at 
90oC and blocking for 20 min with serum-free protein 
block solution before adding anti-klotho antibody 2076 
(1:500) for 20 min. The secondary antibody was donkey 
anti-rat IgG conjugated to horseradish peroxidase (1:10, 
Jackson ImmunoResearch Labs) for 10 min, followed 
by 10 min incubation with EnVision™ FLEX+ high-
sensitivity visualization system in an Autostainer. Five 
min after addition of 3,3’-diaminobenzidine chromogenic 
reagent, the slides were counterstained with hematoxylin 
and examined under a Leica bright field microscope. Five 
microscopic fields with the highest immunoreactivity were 
evaluated independently by three investigators in blinded 
fashion. At least 1,000 cells were analyzed per slide. The 
number of positively-staining cells was estimated, and the 
intensity of staining was scored on a scale of 0 to 3+ (0, 
no staining; 1, weak staining; 2, moderate staining; and 3, 
strong staining). Kidney was the positive control. 
RNA and PCR
Tumor cells (104/well) were grown in RPMI1640 
medium and treated with FGF23, collected by 
centrifugation and washed in phosphate-buffered 
saline (PBS). Plasma cells were isolated from bone 
marrow aspirates using magnetic beads that bind 
CD138 (syndecan-1)-positive cells, according to the 
manufacturer’s instructions (Miltenyi Biotech), yielding 
> 90% pure CD138+ cells by flow cytometry. RNAs were 
extracted from cells from four patients and from MM 
cell lines using Qiagen RNeasy mini kits with DNAse 
treatment, converted to cDNA using Omniscript RT kits 
(Qiagen) with 16mer oligo(dT) primer and analyzed in 
triplicate by real-time (Q-)PCR using Qiagen Quantitect 
SYBR green PCR kits and a Biorad iCycler single-color 
real-time detection system. Ribosomal protein L32 was the 
normalization control [40]. The sequences, design strategy 
and validation for PCR primer sets are given in the 
Supplementary Information. For species-specific PCRs, 
primer sets were tested against mouse and human positive 
templates until sets that give 1000:1 specificity were found 
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[40]. Relative mRNA expression was calculated using the 
∆∆CT method [55]. 
Co-culture of MM cells with bone
MM cell lines were transduced with lentiviral 
particles from GenTarget, according to the manufacturer’s 
instructions, with a vector encoding secreted Gaussia 
luciferase driven by a CMV promoter, plus a GFP-
blasticidin fusion protein cassette. GFP+ MM cells were 
isolated by fluorescence-activated cell sorting. Segments 
of neonatal mouse bone were prepared by a modification 
of Mohammad et al [19]. Calvariae from euthanized 11 
to 14 day-old mouse pups were cut into 4mm disks with 
a biopsy punch and placed into uncoated 24-well plates. 
Luciferase-secreting GFP-MM cells (1x104) were added 
in 0.5ml BGJb medium (Life Technologies) supplemented 
with 20% fetal calf serum, 500nM human insulin and 
100µM ascorbic acid. Plates were incubated at 37°C in 5% 
CO2. Medium was changed every 2-3 days and assayed for 
luciferase as an indicator of tumor burden [21, 22] with a 
BioLux® Gaussia luciferase flex kit (NE BioLabs) and 
a Turner TD 20/20 luminometer. Results were expressed 
as relative luminescence units (RLUs). At day 7, bones 
were washed in PBS, placed in 1.0ml of Qiazol (Qiagen) 
and homogenized for 1 min with zirconium beads in a 
BeadBug microtube homogenizer (Benchmark Scientific) 
at 280 strokes/min, followed by RNA isolation. 
Statistics 
Analyses were performed using Graphpad Prism 5 
and 6. Experiments were performed in replicate and results 
reported as means ± standard deviation, where applicable. 
Expression of mRNA was compared between groups using 
one-way ANOVA with Tukey’s multiple comparison post-
test. Results are shown with mean ± standard deviation, 
where applicable. Degree of significance was represented 
using p values (* = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001).
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